Key Highlights

  • USD 642,889 of third-quarter Revenue for Ainos (NASDAQ:AIMD), against USD 2,167 a year earlier, with USD 600,000 coming from licensing its VELDONA interferon intellectual property.
  • Net loss narrowed 36% to USD 1,886,074 for the quarter, from USD 2,931,702, as Research and Development spending fell 15% to USD 1,696,019.
  • Cash and equivalents were USD 660,916 on September 30, 2026, against USD 16,594,900 of current liabilities, including USD 11,000,000 of convertible notes now due within a year.
  • The filing states that substantial doubt exists about the company continuing as a going concern, with an accumulated Deficit of USD 76,460,933.

A License Payment Turns a Near-Zero Revenue Line Into USD 642,889

Ainos (NASDAQ:AIMD) reported results for the quarter ended September 30, 2026 in a Quarterly Report filed on November 16, 2026. Revenue was USD 642,889, compared with USD 2,167 in the third quarter of 2025. Of that, USD 600,000 came from licensing intellectual property for VELDONA, the company's low-dose oral interferon program, and USD 42,750 from AI Nose devices sold into semiconductor manufacturing. Gross Profit reached USD 536,266, against USD 1,690 a year earlier. Ainos describes itself as a Texas-incorporated company developing AI-enabled scent sensing, which it calls Smell ID, alongside immune therapeutics. Management also reported a licensing framework with a potential value of USD 10 million, covering Sjogren disease and thrombocytopenia first, with room for 15 more indications under future agreements. It also said it completed delivery of 1,400 AI Nose systems under an initial three-year USD 2.1 million arrangement.

Lower Spending Narrows the Quarterly Loss to USD 1,886,074

Operating expenses fell 20% to USD 2,220,938 from USD 2,785,883. Research and development dropped to USD 1,696,019 from USD 1,990,630, and selling, general and administrative costs eased to USD 524,919 from USD 795,253. The loss from operations narrowed to USD 1,684,672 from USD 2,784,193, while interest expense rose to USD 204,763. Net loss was USD 1,886,074 against USD 2,931,702. For the nine months, revenue was USD 643,202 versus USD 113,037 and net loss was USD 8,940,605 versus USD 10,302,714. Adjusted net loss, which excludes share-based pay and depreciation, was USD 672,352 for the quarter. Operating cash outflow for the nine months was USD 3,429,677.

Going-Concern Doubt, Convertible Notes and Thin Cash

The Balance Sheet is the main risk. Cash was USD 660,916, total Assets were USD 18,315,937 and total liabilities were USD 16,594,900, all of them current. The USD 11,000,000 of convertible notes moved to current from non-current, and a Loan payable of USD 2,812,940 was added during the nine months. Stockholders' Equity fell to USD 1,721,037 from USD 7,562,582, and intangible assets make up USD 15,843,468 of assets. After quarter-end the company collected USD 950,000 of receivables, which management says helps liquidity. It also sold 436,857 shares through its at-the-market Facility for USD 830,435 of net proceeds this year. There were 7,554,324 shares outstanding, so further equity sales would dilute holders.

Where Things Stand

The jump came from a one-off license payment, not from a broad sales base. Ainos (NASDAQ:AIMD) turned USD 2,167 of revenue into USD 642,889 mainly through USD 600,000 of VELDONA licensing, and trimmed its net loss to USD 1,886,074. Even so, the company reports substantial doubt about continuing as a going concern, with USD 660,916 of cash and USD 11,000,000 of convertible notes now current. Next markers are further AI Nose orders in semiconductor plants, any additional VELDONA licences, and the next financing.